BioCentury on BioBusiness,
Table: ASCO movers
Back to the parent article
Monday, June 10, 2013
At least eight biotechs
gained or lost more than
10% last week after presenting at the American Society of Clinical Oncology
meeting in Chicago. Clovis Oncology Inc. (NASDAQ:CLVS) topped the list
of gainers after announcing Phase I data for two cancer candidates: CO-1686, a
small molecule that inhibits the T790M EGFR mutant and the initial activating
EGFR mutations, and rucaparib (CO-338), an oral inhibitor of poly(ADP-ribose)
polymerase-1 (PARP-1) and PARP-2. Clovis has rights to CO-1686 from Avila
Therapeutics Inc., which was acquired by Celgene Corp. (NASDAQ:CELG),
and has exclusive, worldwide rights to rucaparib
under a 2011 deal with Pfizer Inc. (NYSE:PFE) (see "Finding a
4-Leaf Clover," A18).
Pharmaceuticals Inc. (NASDAQ:INFI) and Synta Pharmaceuticals Corp. (NASDAQ:SNTA) fell
more than 30% after reporting data that raised concerns from analysts and
investors (see "Analyst Picks & Changes," A23).
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]